News

REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to include adults at increased risk for major adverse ...
PharmExec19h

FDA Expands Indication for Amgen’s Repatha to Include Adults with High LDL-Cholesterol at Increased Risk of Major Cardiovascular Events

New indication positions Repatha as an option for high-risk adults with elevated LDL cholesterol and no prior cardiovascular ...
The Pharma Letter43m

FDA approves broader use of Repatha

The US Food and Drug Administration (FDA) has broadened the approved use of Amgen’s Repatha (evolocumab) to include adults at ...
MedPage Today on MSN1d

First PCSK9 Inhibitor Approved for Blanket Prevention of Heart Disease

Another PCSK9 inhibitor used for cardiovascular protection, alirocumab (Praluent), remains limited to use in people with ...
Pharmabiz4h

Amgen’s Repatha receives US FDA approval for adults at increased risk for MACE due to uncontrolled LDL-C

Amgen’s Repatha receives US FDA approval for adults at increased risk for MACE due to uncontrolled LDL-C: Thousand Oaks, California Tuesday, August 26, 2025, 17:00 Hrs [IST] Amg ...
MPR18h

Repatha Labeling Updated to Expand MACE, HoFH Indications

The Food and Drug Administration (FDA) has expanded the approval of Repatha ® (evolocumab) to include use in adults at increased risk for major adverse cardiovascular events (MACE) due to uncontrolled ...

Dear Doctor: Woman’s recent diagnosis has her on 6 new medications. ‘What about the side effects?’

DEAR DR. ROACH: I am a 52-year-old woman who was diagnosed with familial hypercholesterolemia in October 2024. I went through a cardiac workup for pain in my left arm and found this out.